Home Healthcare Pharmaceuticals Dry Age-Related Macular Degeneration Market

Dry Age-Related Macular Degeneration Market Size, Share & Trends Analysis Report By Stage (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, Above 40 Years), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Dry Age-Related Macular Degeneration Market, By Stage 2022-2034 (USD MILLION/ Units)
    1. Early Age-Related Macular Degeneration
    2. Intermediate Age-Related Macular Degeneration
    3. Late Age-Related Macular Degeneration
  2. Dry Age-Related Macular Degeneration Market, By Age Group 2022-2034 (USD MILLION/ Units)
    1. Above 75 Years
    2. Above 60 Years
    3. Above 40 Years
  3. Dry Age-Related Macular Degeneration Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Injectable
  4. Dry Age-Related Macular Degeneration Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores and Retail Pharmacies
    3. Online Pharmacies
  5. Regional Dry Age-Related Macular Degeneration Market
    1. North America
      1. North America Dry Age-Related Macular Degeneration Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
      2. North America Dry Age-Related Macular Degeneration Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Above 75 Years
        2. Above 60 Years
        3. Above 40 Years
      3. North America Dry Age-Related Macular Degeneration Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      4. North America Dry Age-Related Macular Degeneration Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      5. U.S.
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      6. Canada
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
    2. Europe
      1. Europe Dry Age-Related Macular Degeneration Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
      2. Europe Dry Age-Related Macular Degeneration Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Above 75 Years
        2. Above 60 Years
        3. Above 40 Years
      3. Europe Dry Age-Related Macular Degeneration Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      4. Europe Dry Age-Related Macular Degeneration Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      5. U.K.
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      6. Germany
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      7. France
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      8. Spain
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      9. Italy
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      10. Russia
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      11. Nordic
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      12. Benelux
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      13. Rest of Europe
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
    3. APAC
      1. APAC Dry Age-Related Macular Degeneration Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
      2. APAC Dry Age-Related Macular Degeneration Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Above 75 Years
        2. Above 60 Years
        3. Above 40 Years
      3. APAC Dry Age-Related Macular Degeneration Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      4. APAC Dry Age-Related Macular Degeneration Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      5. China
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      6. Korea
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      7. Japan
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      8. India
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      9. Australia
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      10. Taiwan
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      11. South East Asia
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      12. Rest of Asia-Pacific
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Dry Age-Related Macular Degeneration Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
      2. Middle East and Africa Dry Age-Related Macular Degeneration Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Above 75 Years
        2. Above 60 Years
        3. Above 40 Years
      3. Middle East and Africa Dry Age-Related Macular Degeneration Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      4. Middle East and Africa Dry Age-Related Macular Degeneration Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      5. UAE
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      6. Turkey
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      7. Saudi Arabia
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      8. South Africa
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      9. Egypt
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      10. Nigeria
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      11. Rest of MEA
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
    5. LATAM
      1. LATAM Dry Age-Related Macular Degeneration Market By Stage 2022-2034 (USD MILLION/ Units)
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
      2. LATAM Dry Age-Related Macular Degeneration Market By Age Group 2022-2034 (USD MILLION/ Units)
        1. Above 75 Years
        2. Above 60 Years
        3. Above 40 Years
      3. LATAM Dry Age-Related Macular Degeneration Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
      4. LATAM Dry Age-Related Macular Degeneration Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores and Retail Pharmacies
        3. Online Pharmacies
      5. Brazil
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      6. Mexico
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      7. Argentina
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      8. Chile
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      9. Colombia
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
      10. Rest of LATAM
        1. Early Age-Related Macular Degeneration
        2. Intermediate Age-Related Macular Degeneration
        3. Late Age-Related Macular Degeneration
        4. Above 75 Years
        5. Above 60 Years
        6. Above 40 Years
        7. Oral
        8. Injectable
        9. Hospital Pharmacies
        10. Drug Stores and Retail Pharmacies
        11. Online Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.